Crinecerfont Capsule — FDA Drug Shortage

To Be Discontinued — Neurocrine Biosciences, Inc.

The FDA lists a drug shortage record for Crinecerfont Capsule (capsule) from Neurocrine Biosciences, Inc. with status To Be Discontinued. The shortage was first posted on 04/28/2026.

Shortage Details

Status
To Be Discontinued
Company
Neurocrine Biosciences, Inc.
Package NDC
70370-5025-1
Dosage Form
Capsule
Presentation
Crenessity, Capsule, 25 mg (NDC 70370-5025-1)
Initial Posting
04/28/2026
Revised Date